Hyperlipidemia, Familial Combined
6
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
33%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Genetic Epidemiology of Hypertriglyceridemia
Genomic Dissection of a QTL Affecting the Lipid Profile
Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol
Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia
Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia
Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals